Ironwood Pharmaceuticals Shares Outstanding 2012-2025 | IRWD

Ironwood Pharmaceuticals shares outstanding from 2012 to 2025. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Ironwood Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2024 160
2023 155
2022 186
2021 164
2020 161
2019 156
2018 153
2017 149
2016 145
2015 142
2014 137
2013 116
2012 106
2011 100
Ironwood Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
2025-09-30 178
2025-06-30 177
2025-03-31 161
2024-12-31 160
2024-09-30 160
2024-06-30 159
2024-03-31 158
2023-12-31 155
2023-09-30 187
2023-06-30 155
2023-03-31 187
2022-12-31 186
2022-09-30 184
2022-06-30 185
2022-03-31 190
2021-12-31 164
2021-09-30 165
2021-06-30 163
2021-03-31 162
2020-12-31 161
2020-09-30 160
2020-06-30 160
2020-03-31 160
2019-12-31 156
2019-09-30 157
2019-06-30 156
2019-03-31 155
2018-12-31 153
2018-09-30 153
2018-06-30 152
2018-03-31 151
2017-12-31 149
2017-09-30 150
2017-06-30 149
2017-03-31 148
2016-12-31 145
2016-09-30 145
2016-06-30 145
2016-03-31 144
2015-12-31 142
2015-09-30 142
2015-06-30 142
2015-03-31 141
2014-12-31 137
2014-09-30 139
2014-06-30 138
2014-03-31 130
2013-12-31 116
2013-09-30 121
2013-06-30 113
2013-03-31 108
2012-12-31 106
2012-09-30 114
2012-06-30 107
2012-03-31 104
2011-12-31 100
2011-09-30 100
2011-06-30 100
2011-03-31 99
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.864B $0.351B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $86.784B 32.96
Zoetis (ZTS) United States $55.122B 19.73
Takeda Pharmaceutical (TAK) Japan $51.166B 10.44
Daiichi Sankyo, - (DSNKY) Japan $38.417B 19.13
BeOne Medicines - (ONC) Switzerland $37.465B 198.63
Sandoz Group AG (SDZNY) Switzerland $34.412B 0.00
United Therapeutics (UTHR) United States $20.227B 17.80
Merck (MKKGY) Germany $18.999B 11.71
Shionogi (SGIOY) Japan $15.585B 14.31
Neurocrine Biosciences (NBIX) United States $13.501B 32.40
IPSEN (IPSEY) France $13.099B 0.00
Summit Therapeutics (SMMT) United States $12.994B 0.00
Ionis Pharmaceuticals (IONS) United States $12.867B 0.00
Madrigal Pharmaceuticals (MDGL) United States $11.287B 0.00
Orion OYJ (ORINY) Finland $10.204B 29.15
Eisai (ESAIY) $8.190B 0.00
Ono Pharmaceutical (OPHLF) Japan $6.967B 21.19
Grifols, S.A (GRFS) Spain $6.202B 0.00
Stevanato Group S.p.A (STVN) Italy $5.887B 32.95
Crinetics Pharmaceuticals (CRNX) United States $5.258B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $4.547B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $4.310B 20.46
Indivior (INDV) United States $4.123B 16.83
NewAmsterdam Pharma (NAMS) Netherlands $3.848B 0.00
Corcept Therapeutics (CORT) United States $3.819B 41.26
Centessa Pharmaceuticals (CNTA) United Kingdom $3.123B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.966B 9.46
Hypermarcas (HYPMY) Brazil $2.906B 19.95
Dyne Therapeutics (DYN) United States $2.499B 0.00
Ocular Therapeutix (OCUL) United States $2.433B 0.00
Soleno Therapeutics (SLNO) United States $2.340B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $2.101B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.949B 23.09
Ardelyx (ARDX) United States $1.941B 0.00
Guardian Pharmacy Services (GRDN) United States $1.858B 35.79
Amylyx Pharmaceuticals (AMLX) United States $1.858B 0.00
Harrow (HROW) United States $1.745B 107.09
Oruka Therapeutics (ORKA) United States $1.668B 0.00
Enliven Therapeutics (ELVN) United States $1.615B 0.00
Collegium Pharmaceutical (COLL) United States $1.486B 7.36
BioCryst Pharmaceuticals (BCRX) United States $1.416B 84.00
Relay Therapeutics (RLAY) United States $1.307B 0.00
Xeris Biopharma Holdings (XERS) United States $1.264B 0.00
Savara (SVRA) United States $1.259B 0.00
Evotec AG (EVO) Germany $1.243B 0.00
Aktis Oncology (AKTS) United States $1.033B 0.00
Theravance Biopharma (TBPH) United States $1.032B 43.34
ARS Pharmaceuticals (SPRY) United States $1.032B 0.00
Cronos Group (CRON) Canada $0.996B 0.00
Xencor (XNCR) United States $0.928B 0.00
KalVista Pharmaceuticals (KALV) United States $0.804B 0.00
Nektar Therapeutics (NKTR) United States $0.751B 0.00
Esperion Therapeutics (ESPR) United States $0.712B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.683B 6.10
Bioventus (BVS) United States $0.662B 13.56
ProKidney (PROK) United States $0.647B 0.00
Lexeo Therapeutics (LXEO) United States $0.528B 0.00
Lyell Immunopharma (LYEL) United States $0.512B 0.00
Zevra Therapeutics (ZVRA) United States $0.508B 0.00
Elite Pharmaceuticals (ELTP) United States $0.506B 0.00
Organogenesis (ORGO) United States $0.487B 0.00
Altimmune (ALT) United States $0.482B 0.00
Aclaris Therapeutics (ACRS) United States $0.479B 0.00
Siga Technologies (SIGA) United States $0.477B 6.53
4D Molecular Therapeutics (FDMT) United States $0.439B 0.00
Nature's Sunshine Products (NATR) United States $0.424B 25.24
Aquestive Therapeutics (AQST) United States $0.410B 0.00
USANA Health Sciences (USNA) United States $0.407B 11.35
Cybin (HELP) Canada $0.377B 0.00
Akebia Therapeutics (AKBA) United States $0.364B 0.00
Aldeyra Therapeutics (ALDX) United States $0.300B 0.00
Protara Therapeutics (TARA) United States $0.298B 0.00
Avalo Therapeutics (AVTX) United States $0.292B 0.00
Profound Medical (PROF) Canada $0.290B 0.00
OmniAb (OABI) United States $0.289B 0.00
Achieve Life Sciences (ACHV) Canada $0.289B 0.00
Relmada Therapeutics (RLMD) United States $0.279B 0.00
Larimar Therapeutics (LRMR) United States $0.275B 0.00
Silence Therapeutics (SLN) United Kingdom $0.268B 0.00
Heron Therapeutics (HRTX) United States $0.268B 0.00
Fractyl Health (GUTS) United States $0.254B 0.00
Journey Medical (DERM) United States $0.241B 0.00
Enlivex Therapeutics (ENLV) Israel $0.233B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.221B 0.00
MediWound (MDWD) Israel $0.219B 0.00
Galectin Therapeutics (GALT) United States $0.204B 0.00
AleAnna (ANNA) United States $0.189B 0.00
Minerva Neurosciences (NERV) United States $0.181B 0.00
Innate Pharma SA (IPHYF) France $0.181B 0.00
Century Therapeutics (IPSC) United States $0.178B 0.00
Surrozen (SRZN) United States $0.164B 0.00
Procaps Group, S.A (PROCF) Luxembourg $0.161B 0.00
VAXART, INC (VXRT) United States $0.159B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.152B 0.00
Context Therapeutics (CNTX) United States $0.151B 0.00
Unicycive Therapeutics (UNCY) United States $0.142B 0.00
Inhibikase Therapeutics (IKT) United States $0.132B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.124B 0.00
Incannex Healthcare (IXHL) Australia $0.123B 0.00
Avita Medical (RCEL) United States $0.119B 0.00
Karyopharm Therapeutics (KPTI) United States $0.116B 0.00
Prelude Therapeutics (PRLD) United States $0.114B 0.00
Vivani Medical (VANI) United States $0.110B 0.00
Cassava Sciences (SAVA) United States $0.105B 0.00
Pyxis Oncology (PYXS) United States $0.103B 0.00
Cardiol Therapeutics (CRDL) Canada $0.102B 0.00
Champions Oncology (CSBR) United States $0.098B 41.71
Korro Bio (KRRO) United States $0.089B 0.00
Gain Therapeutics (GANX) United States $0.076B 0.00
Assertio Holdings (ASRT) United States $0.074B 0.00
PolyPid (PYPD) Israel $0.073B 0.00
NRx Pharmaceuticals (NRXP) United States $0.067B 0.00
Acrivon Therapeutics (ACRV) United States $0.066B 0.00
Dominari Holdings (DOMH) United States $0.066B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.066B 54.75
Rafael Holdings (RFL) United States $0.062B 0.00
Metagenomi Therapeutics (MGX) United States $0.061B 0.00
ElectroCore (ECOR) United States $0.061B 0.00
Arch Biopartners (ACHFF) Canada $0.060B 0.00
PMV Pharmaceuticals (PMVP) United States $0.056B 0.00
Nutriband (NTRB) United States $0.054B 0.00
Lipocine (LPCN) United States $0.054B 0.00
Lite Strategy (LITS) United States $0.049B 0.00
Talphera (TLPH) United States $0.047B 0.00
Telomir Pharmaceuticals (TELO) United States $0.045B 0.00
Plus Therapeutics (PSTV) United States $0.041B 0.00
FibroGen (FGEN) United States $0.039B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.038B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.037B 0.00
Wellgistics Health (WGRX) United States $0.036B 0.00
Mural Oncology (MURA) Ireland $0.035B 0.00
Jupiter Neurosciences (JUNS) United States $0.032B 0.00
TherapeuticsMD (TXMD) United States $0.029B 0.00
SCYNEXIS (SCYX) United States $0.028B 0.00
Natural Alternatives (NAII) United States $0.027B 0.00
Klotho Neurosciences (KLTO) United States $0.024B 0.00
Scienture Holdings (SCNX) United States $0.021B 0.00
Cosmos Health (COSM) United States $0.019B 0.00
Traws Pharma (TRAW) United States $0.019B 0.02
Liminatus Pharma (LIMN) United States $0.019B 0.00
VYNE Therapeutics (VYNE) United States $0.019B 0.00
Inotiv (NOTV) United States $0.019B 0.00
Vivos Therapeutics (VVOS) United States $0.017B 0.00
Iterum Therapeutics (ITRM) Ireland $0.017B 0.00
Citius Pharmaceuticals (CTXR) United States $0.017B 0.00
Vyome Holdings (HIND) United States $0.015B 0.00
Mannatech (MTEX) United States $0.014B 0.00
Tempest Therapeutics (TPST) United States $0.013B 0.00
BioLineRx (BLRX) Israel $0.012B 0.00
CASI Pharmaceuticals (CASI) China $0.012B 0.00
Phio Pharmaceuticals (PHIO) United States $0.011B 0.00
China SXT Pharmaceuticals (SXTC) China $0.011B 0.00
Curanex Pharmaceuticals Inc (CURX) United States $0.010B 0.00
Addex Therapeutics (ADXN) Switzerland $0.010B 0.00
Ernexa Therapeutics (ERNA) United States $0.009B 0.00
BioVie (BIVI) United States $0.009B 0.00
Mangoceuticals (MGRX) United States $0.009B 0.00
Ainos (AIMD) United States $0.009B 0.00
Nuvilex (PMCB) United States $0.009B 0.00
TransCode Therapeutics (RNAZ) United States $0.009B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.009B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.008B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.008B 0.00
Biomerica (BMRA) United States $0.007B 0.00
Heatwurx (PCSA) United States $0.007B 0.00
Alaunos Therapeutics (TCRT) United States $0.007B 0.00
Redhill Biopharma (RDHL) Israel $0.007B 0.00
Aptorum Group (APM) United Kingdom $0.006B 0.00
Indaptus Therapeutics (INDP) United States $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.005B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Lyra Therapeutics (LYRA) United States $0.004B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Jaguar Animal Health (JAGX) United States $0.003B 0.00
CDT Equity (CDT) United States $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.002B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.002B 0.00
PainReform (PRFX) Israel $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.001B 0.00
Aditxt (ADTX) United States $0.001B 0.00
SciSparc (SPRC) Israel $0.001B 0.00
Emisphere Technologies (EMIS) United States $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00